---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-138419"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:43:11.165304+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio doses first patient in Phase 1 trial of ADI-270 for advanced clear cell renal cell carcinoma

## Summary
- First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.
- Phase 1 trial is multicenter, open-label, monotherapy; starting dose 3E8 CAR+ cells with option for second dose.
- Company expects to report preliminary Phase 1 clinical data in the first half of 2025.
- Preclinical data showed ADI-270 demonstrated tumor infiltration, resistance to immunosuppressive TME, and potent CAR/innate activity.
- ccRCC is the most common kidney cancer; patients with advanced disease have limited treatment options and high unmet need.

## SEC filing metadata
- accession: 0000950170-24-138419
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/0000950170-24-138419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/acet-20241219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-138419
- JSON: https://secwatch.observer/filing/0000950170-24-138419.json
- Plain text: https://secwatch.observer/filing/0000950170-24-138419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.